Reshma Kewalramani
Profile Verified by The Marque
Last Updated: 22 Sep 2026
CEO & President
Boston, US
Profile Verified by The Marque
Last Updated: 22 Sep 2026
THE MARQUE
In Their Own Right
Biography
Reshma Kewalramani is the CEO and President of Vertex Pharmaceuticals. A highly experienced medical doctor, clinician, researcher and nephrologist, she is well equipped to lead Vertex to its next stage of growth.
She previously held the positions of Executive Vice President, Chief Medical Officer and Senior Vice President. During her time at Vertex, the company has pioneered ground-breaking medical treatments for cystic fibrosis, namely SYMDEKO/SYMKEVI and TRIKAFTA/KAFTRIO, bringing these transformative new therapies to the majority of CF patients around the world.
Formerly, Dr. Kewalramani spent more than 12 years at Amgen in several senior roles, notably as Vice President, Head US Medical Organization. During this time, she expanded Amgen’s Research and Development unit and established the US Medical Organization which oversaw molecular responsibilities.
A passionate doctor, teacher, mentor, philanthropist and STEM advocate, Dr. Kewalramani is active in her community. Amongst many of her other roles and responsibilities, she is a Fellow of the American Society of Nephrology, a board member of the Biomedical Science Careers Program, a member of the Dean’s Advisory Committee at Boston University Medical School, and a board member of RIZE Massachusetts.
Dr. Kewalramani completed her internship and residency at several Mass General Brigham medical centers, including as Resident Physician at Massachusetts General Hospital.
Throughout her notable career, she has earned several accolades, earlier as a leading CEO of a Fortune 500 biotech company and as an International Institute of New England Golden Door Award Honoree. She was most recently recognised on The Time 100 Most Influential People in 2025.
She is an alumnus of Harvard Business School and holds a Summa Cum Laude medical degree from Boston University School of Medicine.
The Record
Background
-
2020 — Present
CEO & President
Vertex Pharmaceuticals
Vertex Pharmaceuticals is a leading biotechnology company that invests in scientific innovation to create transformative new medicines. Dr. Kewalramani previously served as the Chief Medical Officer and Executive Vice President of Global Medicines Development and Medical Affairs from April 2018 through March 2020.
-
Present
Physician
Massachusetts Eye and Ear Infirmary
One of the top centers in the United States for ear and eye treatment. The medical facility is part of the Mass General Brigham integrated health care system.
-
Present
Physician
MIT - Massachusetts Institute of Technology
She worked as a physician at MIT involved in research in the co-stimulatory field.
-
1998 — 2001
Resident Physician
Massachusetts General Hospital
One of the top-ranked hospitals in the United States, delivering on life-affirming health care and research and development that serves the community.
-
2001 — 2002
Nephrology Fellow
Mass General Brigham
Mass General Brigham is a group of medical centers and facilities in the United States with a focus on research and development and excellence in patient treatment and care.
-
2002 — 2004
Nephrologist and Research Fellow
Brigham and Women's Hospital
A leading healthcare facility in the Greater Boston Area, the Brigham and Women's Hospital treats all patients in the facility and on an outpatient basis.
-
2004 — 2017
Vice President, Head US Medical Organization
Amgen
Dr. Kewalramani gained experience in several roles at Amgen, notably, Vice President, Head US Medical Organization; Vice Present, Head Nephrology and Metabolic Therapeutic Area, Global Clinical Development; and other various roles across Global Clinical Development and Medical Affairs.
In The News
Newsfeed
-
26 February 2026 · Time Magazine
Physician-Scientist Reshma Kewalramani Runs One of Biotech’s Biggest Companies
Read more -
16 April 2025 · Time Magazine
100 Most Influential People of 2025: Reshma Kewalramani
Read more -
21 June 2024 · Barron's
Reshma Kewalramani Is Guiding Vertex Pharmaceuticals to Its Next Big Thing
Read more -
15 March 2024 · Statnews
Stat Status List 2024: Reshma Kewalramani
Read more -
15 February 2024 · City of Boston
Mayor Wu Awards $4.7 Million in Funding to Develop Boston's Life Sciences Workforce
Read more -
18 December 2023 · Morningstar
Vertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
Read more -
8 December 2023 · The Daily Mail
FDA approves world-first gene editing treatment: Sickle cell therapy gives hope to 100,000 Americans
Read more -
16 November 2023 · Good Word News
UK approves Vertex and CRISPR therapy for sickle cell disease and beta thalassemia in world first
Read more -
3 November 2023 · The Boston Globe
How a career pivot catapulted Vertex’s CEO to the top of the biotech world
Read more -
5 October 2023 · Boston University Medical Campus
Vertex CEO Reshma Kewalramani, MD’98, Receives 2023 Distinguished Alumni Award
Read more -
20 July 2023 · Boston Business Journal
CEO social leadership award, best corporate-nonprofit partnerships named
Read more -
15 May 2023 · Yahoo! Finance
Babson College Commencement Ceremonies Celebrate the Class of 2023
Read more -
2 May 2023 · Babson College
On Taking Risks and the Relentless Pursuit of Innovation
Read more -
1 May 2023 · India New England News
AIF Boston Gala Raises Over $1.1M, Honors Vertex & CRISPR CEOs Reshma Kewalramani & Samarth Kulkarni
Read more -
21 April 2023 · Harvard Business School
Harvard Business School Honors Five Graduates with 2023 Alumni Achievement Award
Read more -
31 March 2023 · India New England News
AIF to Honor Life Sciences Icons Reshma Kewalramani and Samarth Kulkarni
Read more -
22 September 2022 · Asian American Business Development Center
21st Anniversary of Outstanding 50 Asian Americans in Business Award
Read more -
11 July 2022 · Businesswire
Vertex to Acquire ViaCyte, Goal of Accelerating its Potentially Curative VX-880 Diabetes Programs
Read more -
17 May 2022
Vertex Announces $50 Million Commitment to Health Equity With Three Initial Grants
Read more -
11 April 2022 · PharmExec
Diversity in Action: Q&A With Reshma Kewalramani
Read more -
4 April 2022 · CNBC
Vertex Pharma sees positive results in Phase 2 trials of new non-opioid pain killer
Read more
In Frame
Gallery
Formative Years
Education
-
Boston University School of Medicine
Doctor of Medicine (M.D)/ Summa Cum Laude
1990 — 1998
-
Boston University
Liberal Arts/Medical Education Program; Doctor of Medicine (M.D)
1990 — 1998
-
Harvard Business School Executive Education
Training and Management
Areas Of Focus